ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

About this trial

This clinical trial aims to determine whether a ReDS-guided treatment strategy is superior to the current standard of care for adults hospitalized with heart failure. Additionally, the study will evaluate the safety and cost-effectiveness of this approach.

The study seeks to answer the following key questions:

1. Does the ReDS-guided strategy reduce the risk of cardiovascular events during the first month following hospital discharge? 2. What is the safety profile of this treatment strategy?

Researchers will compare the ReDS-based strategy against the current standard of care. All participants will:

* Undergo daily assessments using the ReDS device throughout their hospitalization. * Attend two follow-up visits post-discharge, scheduled at 2 weeks and 30 days.

Eligibility criteria

Qualifiers

Hospitalized due to heart failure as the main reason, including the presence of symptoms and signs of congestion, regardless of the left ventricular ejection fraction (LVEF).

NT-proBNP greater than 1000 pg/L or BNP greater than 300 pg/L upon admission.

Disqualifiers

Height less than 150 cm or greater than 190 cm or body mass index (BMI) less than 22 or greater than 39, conditions where the use of ReDS is not approved.

Patients requiring inotropes (levosimendan is allowed) or vasopressors upon admission, with mechanical support, or heart transplant recipients.

Any malformation or variant affecting the right lung anatomy (e.g., a pacemaker).

Patients with any heart disease requiring a planned surgical intervention (CABG, valve disease, or other) or percutaneous (TAVR, STE-ACS, mitral or tricuspid valve repair, CRT) during the clinical trial.

Trial design

Treatments tested in this trial

  • Remote Dielectric Sensing System
  • Blinded ReDS data

Treatment groups

1,014 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Lead sponsor

Hospital Universitario Ramon y Cajal

Sponsor institution

Hospital Universitario Ramon y Cajal

Collaborator

Hospital Universitario 12 de Octubre

Collaborator

Hospital San Carlos, Madrid

Collaborator

Hospital Universitario Fundación Jiménez Díaz

Collaborator

Hospital Universitario La Paz

Collaborator

Hospital General Universitario Gregorio Marañon

Collaborator

Hospital Clinic of Barcelona

Collaborator

Hospital Vall d'Hebron

Collaborator

Hospital Universitari de Bellvitge

Collaborator

Hospital del Mar

Collaborator

Hospital Sant Joan Despí Moisès Broggi

Collaborator

Hospital Arnau de Vilanova

Collaborator

Hospital Universitario Virgen de la Arrixaca

Collaborator

Complejo Hospitalario Universitario de Santiago

Collaborator

Salamanca University Hospital

Collaborator

Complejo Hospitalario Toledo

Collaborator

Hospital Universitario Virgen Macarena

Collaborator

Hospital Universitario Reina Sofia de Cordoba

Collaborator

Hospital Universitario Virgen de la Victoria

Collaborator

Hospital Universitario Marqués de Valdecilla

Collaborator

Hospital Clínico Universitario de Valencia

Collaborator

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Collaborator

Puerta de Hierro University Hospital

Collaborator

La Princesa University Hospital Madrid

Collaborator

University Hospital of Girona Dr. Josep Trueta

Collaborator

Joan XXIII University Hospital

Collaborator